These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Davies JK, Koh MB, Lowdell MW. Biol Blood Marrow Transplant; 2004 Apr; 10(4):259-68. PubMed ID: 15077224 [Abstract] [Full Text] [Related]
3. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering. Nonn M, Herr W, Khan S, Todorova M, Link I, Thies J, Distler E, Kaltwasser M, Hoffmann J, Huber C, Hartwig UF. Transplantation; 2008 Nov 27; 86(10):1427-35. PubMed ID: 19034014 [Abstract] [Full Text] [Related]
4. Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxis. Koh MB, Prentice HG, Lowdell MW. Bone Marrow Transplant; 1999 May 27; 23(10):1071-9. PubMed ID: 10373075 [Abstract] [Full Text] [Related]
6. Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Hartwig UF, Nonn M, Khan S, Link I, Huber C, Herr W. Biol Blood Marrow Transplant; 2008 Jan 27; 14(1):99-109. PubMed ID: 18158966 [Abstract] [Full Text] [Related]
7. [Role of TJU103 in prevention of graft-versus-host disease after allogeneic stem cell transplantation in mice]. Wang SB, Guo KY, Hu DM, Yin B. Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun 27; 26(6):810-3. PubMed ID: 16793606 [Abstract] [Full Text] [Related]
8. [Selective depletion of alloreactive T cells and study of anti-tumor activity of specific T cell clones in patients with leukemia]. Matejková E, Ocadlíková D, Smejkalová J, Muzíkova J, Raida L, Tousovská K, Pacasová R, Nenicková M, Tesarová E, Sterba J, Indrák K, Michálek J. Klin Onkol; 2008 Jun 27; 21(3):104-9. PubMed ID: 19097419 [Abstract] [Full Text] [Related]
9. Allogeneic hematopoietic stem cell transplant using mismatched/haploidentical donors. Koh LP, Rizzieri DA, Chao NJ. Biol Blood Marrow Transplant; 2007 Nov 27; 13(11):1249-67. PubMed ID: 17950913 [Abstract] [Full Text] [Related]
15. Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation. Aviner S, Yao X, Krauthgamer R, Gan Y, Goren-Arbel R, Klein T, Tabilio A, McMannis JD, Champlin R, Martelli MF, Bachar-Lustig E, Reisner Y. Hum Immunol; 2005 Jun 27; 66(6):644-52. PubMed ID: 15993710 [Abstract] [Full Text] [Related]
17. Elimination of alloreactive T cells using photodynamic therapy. Boumédine RS, Roy DC. Cytotherapy; 2005 Jun 27; 7(2):134-43. PubMed ID: 16040392 [Abstract] [Full Text] [Related]
18. Selective T-cell depletion for haplotype-mismatched allogeneic stem cell transplantation. Bastien JP, Roy J, Roy DC. Semin Oncol; 2012 Dec 27; 39(6):674-82. PubMed ID: 23206844 [Abstract] [Full Text] [Related]